Recruiting Pulmonary Hypertension Studies in Dothan
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine...
A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis
Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solrikitug in adult participants with eosinophilic esophagitis....
About Pulmonary Hypertension Clinical Trials in Dothan
Pulmonary hypertension is a type of high blood pressure that affects the arteries in the lungs and the right side of the heart. It can lead to heart failure if untreated. Treatment includes vasodilators, endothelin receptor antagonists, and PDE-5 inhibitors.
There are currently 2 pulmonary hypertension clinical trials recruiting participants in Dothan, ALABAMA. These studies are seeking a combined 377 participants. Research is being sponsored by Alkermes, Inc., Uniquity One (UNI). Clinical trial participation is free and participants receive study-related medical care at no cost.
Pulmonary Hypertension Clinical Trials in Dothan — FAQ
Are there pulmonary hypertension clinical trials in Dothan?
Yes, there are 2 pulmonary hypertension clinical trials currently recruiting in Dothan, ALABAMA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Dothan?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Dothan research site will contact you about next steps.
Are clinical trials in Dothan free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Dothan studies also compensate for your time and travel.
What pulmonary hypertension treatments are being tested?
The 2 active trials in Dothan are testing new therapies including novel drugs, biologics, and treatment approaches for pulmonary hypertension.
Data updated March 2, 2026 from ClinicalTrials.gov